Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
A plain-language summary of the cited sources below. Informational only — not medical advice.
Risperidone is an antipsychotic medication that works by blocking certain receptors in the brain — specifically serotonin 5-HT2 and dopamine D2 receptors. By dampening activity at these sites, it can reduce symptoms such as agitation, aggression, and disturbances in thought or perception. It is approved in Australia for treating schizophrenia, acute mania, bipolar I disorder, and severe behavioural disturbances. Once swallowed, the medication is broken down by the liver into an active substance that continues to work in the body; the combined effect lasts around 24 hours, which is why it is usually taken once daily.
Side effects are common and worth monitoring. In clinical trials, more than one in ten people experienced an increase in a hormone called prolactin; this can cause breast swelling, changes in menstrual periods, or milk production unrelated to breastfeeding. Around one in twenty people felt restless and unable to sit still (akathisia), and a similar number experienced headaches or drowsiness. These effects often settle with time, but they can persist and may need a review of the dose or choice of medication.
Rare but serious side effects require urgent medical attention. Neuroleptic malignant syndrome is a life-threatening reaction marked by high fever, severe muscle stiffness, confusion, and unstable blood pressure; it can develop suddenly and needs emergency care. Tardive dyskinesia involves involuntary movements — usually of the face, lips, or tongue — that can become permanent, especially if the medication is used for many months or years. Very rarely, risperidone can cause a dangerous drop in white blood cells (agranulocytosis), severe allergic reactions, or blistering skin conditions such as Stevens-Johnson syndrome. If your family member develops fever, a rash, uncontrolled movements, or seems suddenly unwell, seek medical advice the same day.
Risperidone should not be used in anyone with a known allergy to the medication or any of its inactive ingredients.
Common off-label uses observed in AU practice — none of these are TGA-approved indications for this substance. If the documented purpose is one of these, the prescription falls outside the TGA-approved set and may sit inside the chemical-restraint frame depending on jurisdiction and context.
These are practitioner observations, not TGA-approved indications. A use being off-label does not by itself imply a regulated restrictive practice; review the documented purpose against the observed function in context.
Tier 4 · ObservationBehavioural disturbances Clinical criteria: Treatment Phase: Initial treatment The condition must be characterised by psychotic symptoms and aggression, AND Patient must have dementia of the Alzheimer type, AND Patient must have failed to respond to non-pharmacological methods of treatment, AND Patient must not receive more than 12 weeks of treatment under this restriction. A patient may only qualify for 12 weeks of PBS-subsidised treatment under this restriction once in a 12 month period.
Schizophrenia Clinical criteria: For a patient switching from oral risperidone, the prescriber must determine the patient dosage of this drug based on the current dose of oral risperidone according to the dose transition table in the Therapeutic Goods Administration (TGA) approved Product Information.
“It is a selective monoaminergic antagonist with a high affinity for serotoninergic 5-HT2 and dopaminergic D2 receptors.”
“Risperidone has an elimination half-life of about 3 hours in extensive metabolisers and 17 hours in poor metabolisers. The elimination half-life of 9-hydroxyrisperidone and the active fraction is 24 hours.”
A plain-language summary of the cited sources below. Informational only — not medical advice.
Risperidone is a selective monoaminergic antagonist with high affinity for serotoninergic 5-HT2 and dopaminergic D2 receptors. It is indicated for schizophrenia in adults, acute mania, bipolar I disorder, and behavioural disturbances. Risperidone is metabolised by CYP2D6 to 9-hydroxy-risperidone, which has similar pharmacological activity to the parent compound. After oral administration, risperidone is eliminated with a half-life of approximately 3 hours; the active moiety has an elimination half-life of 24 hours.
Hyperprolactinaemia and elevated blood prolactin are frequent adverse effects. Movement disorders including akathisia and tardive dyskinesia may occur. Neuroleptic malignant syndrome, agranulocytosis, and severe cutaneous reactions including Stevens-Johnson syndrome have been reported. The drug is contraindicated in patients with hypersensitivity to risperidone or any excipient.
Working under the parallel aged-care framework? Aged-care equivalent →
Acute mania Clinical criteria: The condition must be associated with bipolar I disorder, AND The treatment must be as adjunctive therapy to mood stabilisers, AND The treatment must be limited to up to 6 months per episode.
Bipolar I disorder Clinical criteria: The condition must be refractory to treatment, AND The treatment must be in combination with lithium or sodium valproate, AND The treatment must be maintenance therapy.
Severe behavioural disturbances Clinical criteria: Patient must have autism spectrum disorder, AND The treatment must be under the supervision of a paediatrician or psychiatrist, AND The treatment must be in combination with non-pharmacological measures. Population criteria: Patient must be under 18 years of age. Behaviour disturbances are defined as severe aggression and injuries to self or others where non-pharmacological methods alone have been unsuccessful. The diagnosis of autism spectrum disorder must be made based on the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) or ICD-10 international classification of mental and behavioural disorders.
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“Risperidone is partly metabolised by CYP 2D6 to 9-hydroxy-risperidone which has two enantiomers with a similar pharmacological activity as Risperidone.”